|
|
Vaccine Detail
|
SCIB1 DNA vaccine |
| Vaccine Information |
- Vaccine Name: SCIB1 DNA vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: melanoma antigen tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope (NCIT_C91380)
- TRP-2
gene engineering:
- Type: DNA vaccine construction
- Description: This vaccine encodes for melanoma antigein tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope. (NCIT_C91380)
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: This is a DNA-based cancer vaccine that encodes a melanoma antigen tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope and a modified monoclonal antibody, a chimera of human IgG1/murine IgG2a with T cell mimotopes expressed within the complementarity-determining regions (CDR) of the antibodies, with potential immunostimulating and antineoplastic activities. The melanoma TRP2 CTL epitope vaccine SCIB1 expresses the modified antibody. Subsequently, the Fc component of the engineered antibody targets and binds to the CD64 receptor on the dendritic cells (DCs); upon processing by DCs, the cellular immune system may be activated to induce helper T-cell and CTL immune responses against tumor cells expressing the TRP2 antigen. (NCIT_C91380) SCIB1 can be used in combination with either nivolumab (Opdivo) with ipilimumab (Yervoy) or pembrolizumab (Keytruda), standard treatments approved for patients with advanced melanoma. (NCT04079166)
|
| Host Response |
|
|
| References |
NCIT_C91380: Melanoma TRP2 CTL Epitope Vaccine SCIB1 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91380]
NCT04079166: SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study) [https://clinicaltrials.gov/study/NCT04079166]
|
|
